Summary:
The purging efficacy of positive selection of autologous CD34+ PBSC with a clinical scale method of magnetic-activated cell sorting system (CliniMACS) was investigated in 48 patients with non-Hodgkin’s lymphoma (NHL). The median purity and recovery rate of the CD34+ cells post-selection were 93.3% (range 32.6–99.3) and 72.2% (range 20.5–309.8), respectively. The real-time PCR method to detect the patient-specific monoclonal immunoglobulin heavy chain gene rearrangement (minimal residual tumor; MRT) and CD19 and CD20 positivities were used for the detection of contaminating NHL cells before and after CD34+ selection. After selection, the median (range) depletion rate of MRT was 2.53 (1.52–4.78) log, and that of CD19+ cell and CD20+ cell was 2.46 (0.74–3.64) log and 2.32 (0.40–4.01) log, respectively. In 41 patients, high-dose chemotherapy was performed, followed by the transplantation of the isolated CD34+ cells. Rapid neutrophil recovery as well as platelet recovery was seen with a median time to reach 0.5 × 109/l neutrophils of 10 days (range 8–13) and 20 × 109/l platelets of 14 days (range 10–34), respectively. The present study demonstrated that CliniMACS is a highly effective positive selection method and a high purging efficacy could be obtained without compromising the hematopoietic reconstitution capacity of the graft in NHL patients undergoing high-dose chemotherapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med 1995; 333: 1540–1545.
Schenkein DP, Roitman D, Miller KB et al. A phase II multi-center trial of high-dose sequential chemotherapy and peripheral blood stem cell transplantation as initial therapy for patients with high-risk non-Hodgkin’s lymphoma. Biol Blood Marrow Transplant 1997; 3: 210–216.
Haioun C, Lepage E, Gisselbrecht C et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin’s lymphoma: final analysis of the prospective LNH 87-2 protocol – A groupe d'Etude des lymphomas de l'Adulte study. J Clin Oncol 2000; 18: 3025–3030.
Shipp MA, Abeloff MD, Antman KH et al International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin’s lymphomas: report of the jury. J Clin Oncol 1999; 17: 423–429.
Sharp JG, Joshi SS, Armitage JO et al. Significance of detection of occult non-Hodgkin's lymphoma in histologically uninvolved bone marrow by a culture technique. Blood 1992; 79: 1074–1080.
Ratanatharathorn V, Uberti J, Karanes C et al. Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patinents with non-Hodgkin’s lymphoma. Blood 1994; 84: 1050–1055.
Miltenyi S, Muller W, Weichel W et al. High-gradient magnetic cell separation with MACS. Cytometory 1990; 11: 231–238.
Miltenyi S, Guth S, Radbruch A et al. Isolation of CD34+ hematopoietic progenitor cells by high-gradient magnetic cell sorting (MACS). In: Miltenyi S, Thiel A (eds). Hematopietic Stem Cells: The Mulhouse Manual. Alphamed Press: Dayton, OH, USA, 1994, pp 201–213.
Chou T, Ishiguro T, Imajo K et al. A multicenter early phase II study of high-dose chemotherapy with autologous peripheral blood stem cell transplantation for treatment of intermediate grade non-Hodgkin's lymphoma. Jpn J Clin Hematol 1999; 40: 1058–1067.
Cheson BD, Horning SJ, Coiffier B et al Report of an International Workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999; 17: 1244–1253.
Richel DJ, Johnsen HE, Canon J et al. Highly purified CD34+ cells isolated using magnetically activated cell selection provide rapid engraftment following high-dose chemotherapy in breast cancer patients. Bone Marrow Transplant 2000; 25: 243–249.
Shpall EJ, LeMaistre CF, Holland K et al. A prospective randomized trial of buffy coat versus CD34-selected autologous bone marrow support in high-risk breast cancer patients receiving high-dose chemotherapy. Blood 1997; 90: 4313–4320.
Voso MT, Hohaus S, Moos M et al. Autografting with CD34+ peripheral blood stem cells: retained engraftment capability and reduced tumour cell content. Br J Haematol 1999; 104: 382–391.
Henon PR, Liang H, Beckwirth G et al Comparison of hemopoietic and immune recovery after autologous bone marrow or blood stem cell transplants. Bone Marrow Transplant 1992; 9: 285–291.
Roberts MM, To LB, Gillis D et al. Immune reconstitution following peripheral blood stem cell transplantation, autologous bone marrow transplantation and allogeneic bone marrow transplantation. Bone Marrow Transplant 1993; 12: 469–475.
Miyamoto T, Gondo H, Miyoshi Y . Early viral complications following CD34-selected autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Br J Haematol 1998; 100: 348–350.
Holmberg LA, Boeckh M, Hooper H et al Increased incidence of Cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. Blood 1999; 94: 4029–4035.
Friedman J, Lazarus HM, ON Koc . Autologous CD34+ enriched peripheral blood progenitor cell (PBPC) transplantation is associated with higher morbidity in patients with lymphoma when compared to unmanipulated PBPC transplantation. Bone Marrow Transplant 2000; 26: 831–836.
Paulus U, Dreger P, Viehmann K et al. Purging peripheral blood progenitor cellgrafts from lymphoma cells: quantitative comprison of immunomagnetic CD34+ selection systems. Stem Cells 1997; 15: 297–304.
Freedman AS, Neuberg D, Mauch P et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 1999; 94: 3325–3333.
Horning SJ, Negrin RS, Hoppe RT et al. High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete remission: results of a phase II clinical trial. Blood 2001; 97: 404–409.
Schouten HC, Qian W, Kvaloy S et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin’s lymphoma: results form the randomized European CUP trial. J Clin Oncol 2003; 21: 3918–3927.
Magni M, Di Nicola M, Devizzi L et al. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood 2000; 96: 864–869.
Flohr T, Hess G, Kolbe K et al. Rituximab in vivo purging is safe and effective in combination with CD34-positive selected autologous stem cell transplantation for salvage therapy in B-NHL. Bone Marrow Transplant 2002; 29: 769–775.
Acknowledgements
We gratefully acknowledge Kirin Brewery Co. Ltd, Japan for providing the CliniMACS device and support throughout this study.
Author information
Authors and Affiliations
Consortia
Corresponding author
Rights and permissions
About this article
Cite this article
Imai, Y., Chou, T., Tobinai, K. et al. Isolation and transplantation of highly purified autologous peripheral CD34+ progenitor cells: purging efficacy, hematopoietic reconstitution in non-Hodgkin's lymphoma (NHL): results of Japanese phase II study. Bone Marrow Transplant 35, 479–487 (2005). https://doi.org/10.1038/sj.bmt.1704819
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1704819